Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates

Size: px
Start display at page:

Download "Locoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates"

Transcription

1 Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses of agents discussed Why discuss LRT at a transplant conference? Goals of LRT Patients in need of a liver transplant tend to be patients who develop HCC Patients with HCC infrequently good candidates for surgical resection Best chance for cure of unresectable HCC is liver transplant But, wait for an organ can be long and patients run the risk of HCC progressing beyond Milan criteria, hence dropping out LRT can bridge a patient to organ availability Preserve liver transplant candidates with HCC within Milan criteria Milan criteria - no extra-hepatic tumor, single tumor <5cm or </= 3 tumors <3cm Extend survival of patients with HCC even if disease has progressed beyond Milan criteria Downstage HCC to get within Milan Locoregional Therapies for HCC Patients receiving LRT Locoregional Therapies (LRT) consist of percutaneous and trans-arterial treatments LRT may be curative and/or palliative May be used to maintain transplant eligibility in patients with HCC BCLS staging system of HCC Bruit, J Sherman, M Management of Hepatocellular Carcinoma. Hepatology 2005; 42:

2 Thermal Ablation Radio frequency (RF) Cryoablation Microwave Electroporation Percutaneous Ethanol Injection (PEI) Generally reserved for 3 or fewer tumors Typically tumors are <3cm in size Tumors must be safely accessible percutaneously Ablation feasibility and success influenced by adjacent structures (e.g. heat sink from large vessels or potential for damage to unintended target) Percutaneous ethanol injection (PEI) Effective in small tumors Less concern about adjacent organs or heat sink Usually requires multiple treatments Largely supplanted by thermal techniques in the US Radiofrequency (RF) ablation Complete ablation of small to medium sized tumors in a single session in 80% and >90% in 2 sessions* 5 year survival 40-58% compared to overall 5 year survival for HCC in Europe and US of <10%* Limited by heat sink effect of adjacent vessels, inability to achieve lethal temperature in large tumors Risks include hemorrhage, bile duct injury, abscess, adjacent organ or intestinal damage, tumor tract seeding *McWilliams, et al JVIR 2010; 21:s204-s213 Microwave (MW) ablation Similar to RF in that heat is used to induce coagulation necrosis Shorter treatment time Less heat sink effect Overall results and complications similar to RF* *McWilliams, et al JVIR 2010; 21:s204-s213 2

3 Cryoablation Uses cyclical application of low temperatures Requires less anesthetic Less frequently deployed in liver because it usually requires more, and larger, probes than RF or MW So far, cryoablation has been less effective and more prone to complications* New/experimental MR guided High intensity focused ultrasound (HiFU) Irreversible electroporation (IE) *McWilliams, et al JVIR 2010; 21:s204-s213 Bland embolization Conventional chemoembolization (TACE) Drug-eluting bead chemoembolization (DEB- TACE) Principles of trans-arterial treatment of HCC most tumors in the liver are supplied by primarily by branches of the proper hepatic artery while normal liver is primarily supplied by branches of the portal vein agents delivered to the liver via branches of the proper hepatic artery are relatively concentrated in tumors with relative sparing of the normal hepatic parenchyma Bland embolization Introduction of small particles into branches of the proper hepatic artery (lobar or superselective) with intent to induce ischemic necrosis of tumors 3

4 Trans-arterial chemo-embolization (TACE) Introduction of chemotherapy drug(s) via branches of the proper hepatic artery (lobar or superselective) for treatment of liver tumors Embolic particles are injected after the chemotherapeutic drugs *There is no FDA approved drug regimen for TACE despite relatively long experience with this procedure and most drugs used for TACE have recently been removed from the market. This disruption in supply has removed conventional TACE as an option for treatment locally. Chemo-embolization with Drug Eluting Beads (DEB-TACE) Chemotherapy drug loaded into specially designed embolic particles. Drug slowly eluted from particles after injection. Relatively new. Protocols are evolving. Most commonly used TACE drug (doxorubicin) can be used in DEB-TACE Advantages over TACE include less systemic effects of chemotherapeutic agent (less nausea and malaise) and greater intra-tumoral concentration of chemotherapeutic agent Not yet proven to offer survival benefit over TACE but presumed to be at least equivalent Untreated HCC survival Survival data for TACE 32% survival at 6 months* Median survival 1.6 months (8.3 months for Okuda stage 1) Survival benefits of TACE well demonstrated in case control and retrospective studies compared to untreated patients Survival rates after TACE of 64%, 38%, 27% and 27% at 1, 2, 3, and 4 years respectively* Compared to 18%, 6%, and 5% at 1, 2, and 3 years for untreated, case-control patients *Okuda, et al. Cancer 1985; 56: *Bronowicki, et al. Cancer 1994; 74:16-24 Survival data for TACE DEB-TACE survival Few attempts at true RCT of TACE. Many flawed attempts failed to show benefit of TACE* Median survival of 54.2 months for BCLC-A and 47.7 months for BCLC-B* *Ramsey, et al. JVIR 2002; 13:s211-s221 *Burrel, et al. Hepatology 2012: 56:

5 (aka selective internal radiation therapy) Introduction of radiation emitting embolic particles into branches of the proper hepatic artery (lobar or superselective) Yttrium-90 (a beta emitter) can be loaded onto embolic particles. Emitted radiation travels up to 11 mm and delivers radiation for approximately 2 weeks (half life is 64 hours) DEB TACE v. Y-90 embolization for HCC is hotly debated within IR. Two companies produce Y-90 loaded particles and insurance coverage is variable (total treatment costs >$100k) First Y-90 case in South Dakota 69 year old previously healthy patient with vague abdominal pain found to have large tumor in liver. Biopsy proven to be HCC (not the typical path to diagnosis but patient was not cirrhotic). 7/30/2010 After first round of chemo-embolization 10/8/2010 After 3 rounds of chemo-embolization 12/31/2011 Still not transplant candidate Post bilobar radio-embolization 4/18/2014 5

6 Patient alive 3/31/2016 at age 74, nearly 6 years after diagnosis TACE achieved objective response, Y-90 made patient transplant candidate, transplant provided cure Post transplant 12/2/2014 Y-90 survival data Median survival after SIRT for HCC* 24.4 months for BCLC-A 16.9 months for BCLC-B 10.0 months for BCLC-C *Sangro, et al. Hepatology 2011; 54: SIRT v. TACE From abstract to be presented by Northwestern group at SIR 2016 this week* 43 patients (BCLC A/B, Child-Pugh A/B) randomized to ctace v. glass Y-90 SIRT resulted in significantly longer TTP (not reached v. 6.4 months) Trend towards survival benefit SIRT resulted in lower dropout from transplant listing (13/18 v. 6/15) *Gordon, et al. JVIR 2016; 27: s61-s62 LRT increases the likelihood of transplant, specifically for patients with long wait times* LRT is successful in keeping patients on the wait list* In a retrospective study, median survival within Milan criteria was 644 days for patients receiving LRT and 162 days for patients receiving supportive care (survival follow-up truncated at death, exceeding Milan, transplant or study end) *Sheth, et al. JVIR 2015; 26: Dhaneskaran, et al JVIR 2010; 21:

7 In patients not receiving transplant, median survival is 502 days with LRT, 151 days without Dhaneskaran, et al JVIR 2010; 21:

Locoregional Therapy for Hepatoma

Locoregional Therapy for Hepatoma Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish

More information

Liver Directed Therapy for Hepatocellular Carcinoma

Liver Directed Therapy for Hepatocellular Carcinoma Liver Directed Therapy for Hepatocellular Carcinoma Anil K Pillai MD, FRCR, Associate Professor, Department of Radiology UT Houston Health Science Center, Houston, TX, United States. Hepatocellular cancer

More information

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center

Hepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer

More information

Staging & Current treatment of HCC

Staging & Current treatment of HCC Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt

More information

Guidelines for SIRT in HCC An Evolution

Guidelines for SIRT in HCC An Evolution Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early

More information

HCC RADIOLOGIC DIAGNOSIS

HCC RADIOLOGIC DIAGNOSIS UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,

More information

Hepatocellular Carcinoma: Diagnosis and Management

Hepatocellular Carcinoma: Diagnosis and Management Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm

More information

Regional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine

Regional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Regional Therapy for Metastatic Neuroendocrine Tumors Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Introduce regional therapy for mnet Arterial therapies Injection

More information

Ruolo della interventistica per le secondarietà epatiche e di altre sedi

Ruolo della interventistica per le secondarietà epatiche e di altre sedi Ruolo della interventistica per le secondarietà epatiche e di altre sedi Giancarlo Bizzarri Dipartimento di Diagnostica per Immagini e Radiologia Interventistica Ospedale Regina Apostolorum, Albano Laziale

More information

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?

WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views

More information

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page

The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed

More information

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines

Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in

More information

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine

More information

State-of-the-art minimally invasive interventions for liver tumors

State-of-the-art minimally invasive interventions for liver tumors William Lo, HMS MD/PhD candidate, MS III Gillian Lieberman, MD State-of-the-art minimally invasive interventions for liver tumors William Lo, HMS MD/PhD candidate, MS III Gillian Lieberman, MD

More information

Liver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties

Liver Tumors. Patient Education. Treatment options 8 4A. About the Liver. Surgical Specialties Patient Education Treatment options This handout describes different kinds of tumors that form in the liver and how they are treated. About the Liver Your liver is the largest organ in your abdomen. It

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD

TREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE

More information

Liver Cancer: Diagnosis and Treatment Options

Liver Cancer: Diagnosis and Treatment Options Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration

6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration

More information

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC

MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Cryosurgical Ablation of Primary or Metastatic Liver Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cryosurgical_ablation_of_primary_or_metastatic_liver_tumors

More information

Interventional Radiologic Treatment of Hepatocellular Carcinoma

Interventional Radiologic Treatment of Hepatocellular Carcinoma Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular

More information

HCC: Is it an oncological disease? - No

HCC: Is it an oncological disease? - No June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -

More information

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which

More information

TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD

TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD UNIVERSITY OF PRETORIA STEVE BIKO ACADEMIC HOSPITAL SOUTH AFRICA TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD 1 INTRODUCTION Hepatic

More information

Paul Martin MD FACG. University of Miami

Paul Martin MD FACG. University of Miami Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28

More information

Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?

Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:

More information

EASL-EORTC Guidelines

EASL-EORTC Guidelines Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according

More information

RF Ablation: indication, technique and imaging follow-up

RF Ablation: indication, technique and imaging follow-up RF Ablation: indication, technique and imaging follow-up Trongtum Tongdee, M.D. Radiology Department, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand Objective Basic knowledge

More information

Treatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center

Treatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new

More information

Disclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:

Disclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company

More information

Embolotherapy for Cholangiocarcinoma: 2016 Update

Embolotherapy for Cholangiocarcinoma: 2016 Update Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial

More information

LIVER DIRECTED THERAPIES FOR PATIENTS WITH UNRESECTABLE METASTASES

LIVER DIRECTED THERAPIES FOR PATIENTS WITH UNRESECTABLE METASTASES LIVER DIRECTED THERAPIES FOR PATIENTS WITH UNRESECTABLE COLORECTAL CANCER LIVER METASTASES Jaime R. Merchan, MD, MMSc Associate Professor of Medicine Division of Hematology-Oncology University of Miami

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 114 Effective Health Care Program Local Therapies for Unresectable Primary Hepatocellular Carcinoma Executive Summary Introduction Background This comparative effectiveness

More information

Radiofrequency Ablation versus Microwave Ablation in HCC and Liver Metastases

Radiofrequency Ablation versus Microwave Ablation in HCC and Liver Metastases Radiofrequency Ablation versus Microwave Ablation in HCC and Liver Metastases Thomas J. Vogl, B. Panahi, N. Nour-Eldin I D I R: Institute of Diagnostic and Interventional Radiology Goethe University Frankfurt,

More information

Hamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE.

Hamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE. Hamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE. YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA EFFICACY AND SAFETY OF YTTRIUM-90 RADIO- EMBOLIZATION

More information

UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA

UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the

More information

Pamplona, junio de Futuro de la Hepatología: Cáncer Hepático. Bruno Sangro Clínica Universidad de Navarra. IDISNA. CIBERehd.

Pamplona, junio de Futuro de la Hepatología: Cáncer Hepático. Bruno Sangro Clínica Universidad de Navarra. IDISNA. CIBERehd. Pamplona, junio de 2008 Futuro de la Hepatología: Cáncer Hepático Bruno Sangro Clínica Universidad de Navarra. IDISNA. CIBERehd. Pamplona, Spain Etiología del Cáncer Hepático HBV HCV Alcohol NAFLD Iron

More information

SIRT for Intermediate and Advanced HCC

SIRT for Intermediate and Advanced HCC Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro

More information

TACE: coming of age?

TACE: coming of age? Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology

More information

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies

Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue

More information

Liver resection for HCC

Liver resection for HCC 8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of selective internal radiation therapy for primary liver cancer Selective internal

More information

8/1/2017. Disclosures. Outline. SAM Imaging Education Course 90Y-Microsphere Therapy: Emerging Trends and Future Directions

8/1/2017. Disclosures. Outline. SAM Imaging Education Course 90Y-Microsphere Therapy: Emerging Trends and Future Directions SAM Imaging Education Course Y-Microsphere Therapy: Emerging Trends and Future Directions Matt Vanderhoek, PhD Henry Ford Health System, Detroit, MI Vanessa Gates, MS Northwestern University, Chicago,

More information

Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Radiofrequency Ablation of Primary or Metastatic Liver Tumors Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)

More information

Current Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005

Current Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005 Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially

More information

100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days

100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days 100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

treatment options for primary liver malignancies and metastatic disease

treatment options for primary liver malignancies and metastatic disease State of the art treatment options for primary liver malignancies and metastatic disease Peter Huppert Prof. of Radiology and Neuroradiology Klinikum Darmstadt Certified Vascular and Oncologic Center Disclosure

More information

EPIDEMIOLOGY. Long established risk factors for CCA: hepatobiliaryflukes, PSC, biliary tract cysts, epatolithiasis.

EPIDEMIOLOGY. Long established risk factors for CCA: hepatobiliaryflukes, PSC, biliary tract cysts, epatolithiasis. EPIDEMIOLOGY Intrahepatic cholangiocarcinoma(icc) is the second most common (15%) primary liver cancer after hepatocellular carcinoma (HCC), with a rate of about 2.1/100,000 people per year in western

More information

RADIATION SEGMENTECTOMY. Robert J Lewandowski, MD

RADIATION SEGMENTECTOMY. Robert J Lewandowski, MD RADIATION SEGMENTECTOMY Robert J Lewandowski, MD Robert Lewandowski, M.D. Consultant/Advisory Board: Cook Medical, LLC, Arsenal, BTG International, Boston Scientific Corp., ABK Reference Unlabeled/Unapproved

More information

Liver Tumors. Prof. Dr. Ahmed El - Samongy

Liver Tumors. Prof. Dr. Ahmed El - Samongy Liver Tumors Prof. Dr. Ahmed El - Samongy Objective 1. Identify the most important features of common benign liver tumors 2. Know the risk factors, diagnosis, and management of hepatocellular carcinoma

More information

Damian Dupuy, MD. Image Guided Intervention (IGI) Studies 10:25 11:05 AM

Damian Dupuy, MD. Image Guided Intervention (IGI) Studies 10:25 11:05 AM Damian Dupuy, MD Image Guided Intervention (IGI) Studies 10:25 11:05 AM Image Guided Intervention (IGI) Studies Damian E. Dupuy, M.D., FACR Professor of Diagnostic Imaging The Warren Alpert Medical School

More information

9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES

9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report

More information

Management of Stage IV Colorectal Cancer: Expanding the Horizon

Management of Stage IV Colorectal Cancer: Expanding the Horizon Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures

More information

Radioembolization for Primary and Metastatic Tumors of the Liver

Radioembolization for Primary and Metastatic Tumors of the Liver Radioembolization for Primary and Metastatic Tumors of the Liver Policy Number: 8.01.43 Last Review: 8/2017 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization

Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization Department of Radiology, National Cancer Center In Joon Lee Contents Conventional TACE Role of TACE in management

More information

The Role of Interventional Radiology (Locoregional

The Role of Interventional Radiology (Locoregional The Role of Interventional Radiology (Locoregional therapies) in HCC Richard Owen MB, MRCP, FRCR Interventional Radiology, Associate Professor University of Alberta Aldo Montana-Loza MD, FRCPC Hepatology

More information

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies

Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its

More information

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies

More information

Advances in percutaneous ablation for hepatocellular carcinoma

Advances in percutaneous ablation for hepatocellular carcinoma Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France

More information

Description. Section: Therapy Effective Date: July 15, 2014 Subsection: Therapy Original Policy Date: June 7, 2012 Subject: Page: 1 of 23

Description. Section: Therapy Effective Date: July 15, 2014 Subsection: Therapy Original Policy Date: June 7, 2012 Subject: Page: 1 of 23 Last Review Status/Date: June 2014 Page: 1 of 23 Description Radioembolization (RE), referred to as selective internal radiation therapy or SIRT in older literature, is the intra-arterial delivery of small

More information

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network

More information

Index. C Cancer, Carcinoid syndrome, 413. D DCIS. See Ductal carcinoma in situ (DCIS) DEB-TACE. See Drug eluting beads-tace (DEB-TACE)

Index. C Cancer, Carcinoid syndrome, 413. D DCIS. See Ductal carcinoma in situ (DCIS) DEB-TACE. See Drug eluting beads-tace (DEB-TACE) Index A Ablation, 179 199, 843 853 devices, 179, 199 liver tumors, 527 techniques, 516 Ablative radiation therapy, 456 Accelerated partial breast, 894, 896 898 Adaptive radiation therapy, 586, 598, 602

More information

Hepatocellular carcinoma: Intra-arterial treatments

Hepatocellular carcinoma: Intra-arterial treatments Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA

More information

Radioembolization for Primary and Metastatic Tumors of the Liver

Radioembolization for Primary and Metastatic Tumors of the Liver Page: 1 of 28 Last Review Status/Date: September 2015 Description Radioembolization (RE), also referred to as selective internal radiotherapy (SIRT), is the intra-arterial delivery of small beads (microspheres)

More information

Management of HepatoCellular Carcinoma

Management of HepatoCellular Carcinoma 9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma

More information

in Hepatocellular Carcinoma

in Hepatocellular Carcinoma in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):

More information

UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA*

UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA* UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA* Dr. Catherine Frenette Medical Director of Liver Transplantation, Scripps Green Hospital, La Jolla, CA, USA May 2018

More information

Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation

Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v19.i43.7515 World J Gastroenterol 2013 November 21; 19(43): 7515-7530 ISSN 1007-9327 (print) ISSN 2219-2840 (online)

More information

New Energy Sources for Local Ablation Therapy. Jeong Kyong Lee, MD Ewha Womans University

New Energy Sources for Local Ablation Therapy. Jeong Kyong Lee, MD Ewha Womans University New Energy Sources for Local Ablation Therapy Jeong Kyong Lee, MD Ewha Womans University New Energy Sources for Local Ablation Therapy Microwave Ablation Irreversible Electroporation Cryoablation Microwave

More information

Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College

More information

Radioembolization for Primary and Metastatic Tumors of the Liver

Radioembolization for Primary and Metastatic Tumors of the Liver Radioembolization for Primary and Metastatic Tumors of the Liver Policy Number: 8.01.43 Last Review: 8/2018 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Transcatheter hepatic arterial chemoembolization may be considered medically necessary to

Transcatheter hepatic arterial chemoembolization may be considered medically necessary to Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Hepatocellular carcinoma Transcatheter hepatic arterial chemoembolization

More information

December 12 th 2017 CM) INTERVENTIONAL ONCOLOGY 09:00 REGISTRATION

December 12 th 2017 CM) INTERVENTIONAL ONCOLOGY 09:00 REGISTRATION December 12 th 2017 09:00 REGISTRATION 09:30 10:30 LYMPHONODES AND ADRENAL METASTASES Lymphonodes metastases clinical assessment Lymphonodes metastases imaging assessment and percutaneous treatments Adrenal

More information

DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE?

DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE? DEB-TACE vs Conventional TACE in Intermediate HCC: Best Candidates for DEB-TACE? Ho Jong Chun, MD., PhD Seoul St. Mary s Hospital, The Catholic University of Korea Why Drug-eluting Beads? Clear Rationale

More information

The Role of Interventional Radiology in Cancer and Palliative Care. David T. Wang, D.O.

The Role of Interventional Radiology in Cancer and Palliative Care. David T. Wang, D.O. The Role of Interventional Radiology in Cancer and Palliative Care David T. Wang, D.O. Disclosures None Objectives Give an overview of the role Interventional Radiology can play in Cancer and Palliative

More information

Medical Policy. MP Radiofrequency Ablation of Primary or Metastatic Liver Tumors

Medical Policy. MP Radiofrequency Ablation of Primary or Metastatic Liver Tumors Medical Policy MP 7.01.91 BCBSA Ref. Policy: 7.01.91 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 7.01.75 Cryosurgical Ablation of Primary or Metastatic Liver Tumors

More information

MANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011

MANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011 MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal

More information

Update EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma

Update EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma Update EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma Peter R. Galle PHC 2018 - www.aphc.info Disclosure of Conflict of Interest Peter R. Galle I have the following financial

More information

Transarterial Chemoembolisation (TACE) with Drug-Eluting Beads

Transarterial Chemoembolisation (TACE) with Drug-Eluting Beads Transarterial Chemoembolisation (TACE) with Drug-Eluting Beads A minimally invasive treatment for liver cancer Provided as an educational service by Biocompatibles UK Ltd, a BTG International group company

More information

Radiofrequency Ablation of Liver Tumors

Radiofrequency Ablation of Liver Tumors Radiofrequency Ablation of Liver Tumors Michael M. Awad, Michael A. Choti Indications and Contraindications Indications Unresectable malignant tumors of the liver (e.g., hepatocellular carcinoma, colorectal

More information

Hepato-Pancreatico-Biliary Surgery. Dr. Ankur J. Shah. MS, DNB, MNAMS, MRCSEd (UK), FRCS (UK)

Hepato-Pancreatico-Biliary Surgery. Dr. Ankur J. Shah. MS, DNB, MNAMS, MRCSEd (UK), FRCS (UK) Hepato-Pancreatico-Biliary Surgery Dr. Ankur J. Shah MS, DNB, MNAMS, MRCSEd (UK), FRCS (UK) Consultant Hepato-Pancreatico-Biliary and Liver Transplant Surgeon Ansh Liver Clinic Prevention to Cure Address

More information

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging

Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery

More information

IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS

IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS UnitedHealthcare Commercial Medical Policy IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS Policy Number: 2018T0445O Effective Date: February 1, 2018 Table of Contents Page INSTRUCTIONS

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

SELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER

SELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER SELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER SIR-Spheres*: A New Treatment Option for Non-Resectable Liver Tumors Treatment Overview SIRT: Selective Internal Radiation Therapy Concept

More information

Management of Colorectal Liver Metastases

Management of Colorectal Liver Metastases Management of Colorectal Liver Metastases MM Bernon, JEJ Krige HPB Surgical Unit, Groote Schuur Hospital Department of Surgery, University of Cape Town 50% of patients with colorectal cancer develop liver

More information

Disclosures. I am on the Onyx speaker bureau I am a paid consultant to. Boston Scientific CeloNova Cook MDS Nordion Sirtex

Disclosures. I am on the Onyx speaker bureau I am a paid consultant to. Boston Scientific CeloNova Cook MDS Nordion Sirtex Disclosures I am on the Onyx speaker bureau I am a paid consultant to Boston Scientific CeloNova Cook MDS Nordion Sirtex Comparing Y90 Devices Matthew S. Johnson MD, FSIR Indiana University School of Medicine

More information

Description. Section: Surgery Effective Date: October 15, 2014 Subsection: Surgery Original Policy Date: December 7, 2011 Subject:

Description. Section: Surgery Effective Date: October 15, 2014 Subsection: Surgery Original Policy Date: December 7, 2011 Subject: Last Review Status/Date: September 2014 Page: 1 of 20 Description In radiofrequency ablation (RFA), a probe is inserted into the center of a tumor and the noninsulated electrodes, which are shaped like

More information

IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS

IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS UnitedHealthcare Oxford Clinical Policy IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS Policy Number: CANCER 036.11 T2 Effective Date: May 1, 2018 Table of Contents Page INSTRUCTIONS

More information

SBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment

SBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment SBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment Nima Nabavizadeh, MD Assistant Professor Division Leader Hematologic Malignancies Co-division Leader Gastrointestinal

More information

Interventional Oncology Patient Awareness

Interventional Oncology Patient Awareness Interventional Oncology Patient Awareness Interventional Radiology: your minimally invasive alternative www.cirse.org Cardiovascular and Interventional Radiological Society of Europe Cardiovascular and

More information

Latest Developments in the Treatment of Hepatocellular Carcinoma

Latest Developments in the Treatment of Hepatocellular Carcinoma Latest Developments in the Treatment of Hepatocellular Carcinoma Roniel Cabrera, MD MS Associate Professor of Medicine Director of Hepatology and Medical Director of Liver Transplantation Division of Gastroenterology,

More information

Percutaneous ablation: indications, techniques and results

Percutaneous ablation: indications, techniques and results Percutaneous ablation: indications, techniques and results Giovan Giuseppe Di Costanzo Dipartimento dei Trapianti UOSC Epatologia AORN A Cardarelli - Napoli Treatment algorithm EASL, EORTC guidelines HCC

More information

SIR- RFS Journal Primer

SIR- RFS Journal Primer Comparison of Combina-on Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboliza-on with Radiofrequency Abla-on versus Microwave Abla-on SIR- RFS Journal Primer Quick Summary

More information

Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma

Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma International Course on THERANOSTICS and MOLECULAR RADIOTHERAPY Brussels, 4 october 2017 Vincent Donckier

More information